Ropes & Gray represented Zai Lab Limited in the offering, while Simpson Thacher & Bartlett represented the underwriters. Zai Lab Limited (“Zai Lab” or the “Company”)...
Zai Lab’s $200 Million Secondary Offering
Kailera Therapeutics’ $400 Million Series A Financing
Ropes & Gray advised Kailera Therapeutics, Inc. on the transaction. Kailera Therapeutics, Inc. (“Kailera”) announced raising $400 million in Series A financing. Kailera announced its launch...
Shanghai Voicecomm Information Technology’s US$85 Million Initial Public Offering
Ashurst acted as the U.S. counsel to Shanghai Voicecomm Information Technology, while O’Melveny represented the underwriters on the offering. Shanghai Voicecomm Information Technology Co., Ltd. (2495.HK)...
Laopu Gold’s HK$906 Million HKEX IPO
On the deal, O’Melveny acted for Laopu Gold, Linklaters advised the underwriters. Laopu Gold Co., Ltd. completed the global offering and listing of H shares on...
Becton, Dickinson and Company’s Acquisition of Critical Care Product Group of Edwards Lifesciences
Skadden is advising Edwards Lifesciences, while Ropes & Gray is providing legal counsel to BD on the deal. Edwards Lifesciences has entered into a definitive agreement...
Takeda Pharmaceuticals’ $1.2 Billion License Agreement with Degron Therapeutics
Ropes & Gray advised Takeda Pharmaceuticals on the deal. Takeda Pharmaceuticals announced it has entered into a collaboration and exclusive license agreement with Degron Therapeutics (“Degron”)...
Qyuns Therapeutics’ US$31 Million Initial Public Offering
O’Melveny represented China International Capital Corporation Hong Kong Securities Limited as the sole sponsor and overall coordinator in the IPO. Qyuns Therapeutics Co., Ltd. (2509.HK) announced...
Allorion Therapeutics’ Licensing Agreement with Avenzo Therapeutics
Ropes & Gray advised Allorion Therapeutics on the transaction. Allorion Therapeutics (Allorion) announced it entered into a global licensing agreement with Avenzo Therapeutics Inc. (Avenzo) to develop and...
LianBio’s License Agreement with Bristol Myers Squibb
Ropes & Gray represented LianBio on the deal. LianBio (Nasdaq: LIAN) announced it has entered into an agreement with Bristol Myers Squibb (NYSE:BMY)(BMS), whereby BMS has obtained...
Beijing Fourth Paradigm Technology’s $150 Million Initial Public Offering
O’Melveny represented the sole sponsor, the coordinators and the underwriters in the transaction. Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) announced its initial public offering and listing...
HUTCHMED’s License Agreement with Takeda Pharmaceutical
Ropes & Gray represented HUTCHMED on the deal. HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited announced an exclusive worldwide license agreement with Japan’s largest drugmaker Takeda...
Beauty Farm’s Hong Kong IPO and Listing
O’Melveny advised Beauty Farm. Clifford Chance has advised the joint sponsors. Shearman & Sterling advised Beijing Xinyu Meiye Holdings Limited as a selling shareholder. Beauty Farm...